(vianews) - merck and co inc (mrk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| merck and co inc (mrk.pa) | €97.30 | 2.86% | 34.46% |
| medistim (medi.ol) | kr296.00 | 1.33% | 33.83% |
| tubize-fin (tub.br) | €76.00 | 1.12% | 9.88% |
| biomerieux (bim.pa) | €96.56 | 0.88% | 12.93% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. merck and co inc (mrk.pa)
2.86% forward dividend yield and 34.46% return on equity
merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.
earnings per share
as for profitability, merck and co inc has a trailing twelve months eps of €5.23.
pe ratio
merck and co inc has a trailing twelve months price to earnings ratio of 18.6. meaning, the purchaser of the share is investing €18.6 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.46%.dividend yield
as stated by morningstar, inc., the next dividend payment is on mar 14, 2023, the estimated forward annual dividend rate is 2.76 and the estimated forward annual dividend yield is 2.86%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, merck and co inc's stock is considered to be oversold (<=20).
yearly top and bottom value
merck and co inc's stock is valued at €97.30 at 22:30 est, way under its 52-week high of €109.00 and way higher than its 52-week low of €72.50.
revenue growth
year-on-year quarterly revenue growth grew by 2.3%, now sitting on 59.28b for the twelve trailing months.
more news about merck and co inc.
2. medistim (medi.ol)
1.33% forward dividend yield and 33.83% return on equity
medistim asa develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the united states, europe, asia, and internationally. it offers miraq cardiac, a system that combines ultrasound imaging and transit time flow measurement (ttfm) in a single system for cardiac surgery; miraq vascular, a system that combines ultrasound imaging and transit ttfm in a single system for vascular surgery; and imaging probes for intraoperative use. the company also provides various flow probes, such as quickfit ttfm probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; vascular ttfm probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. in addition, it distributes and sells third party medical equipment. the company was incorporated in 1984 and is headquartered in oslo, norway.
earnings per share
as for profitability, medistim has a trailing twelve months eps of kr5.67.
pe ratio
medistim has a trailing twelve months price to earnings ratio of 52.2. meaning, the purchaser of the share is investing kr52.2 for every norwegian krone of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.83%.stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, medistim's stock is considered to be oversold (<=20).
sales growth
medistim's sales growth is 26% for the ongoing quarter and 10.2% for the next.
yearly top and bottom value
medistim's stock is valued at kr296.00 at 22:30 est, way under its 52-week high of kr330.00 and way above its 52-week low of kr184.80.
moving average
medistim's worth is way higher than its 50-day moving average of kr237.47 and way above its 200-day moving average of kr245.35.more news about medistim.
3. tubize-fin (tub.br)
1.12% forward dividend yield and 9.88% return on equity
financière de tubize sa, through its interest in ucb, operates as a biopharmaceutical company worldwide. it discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. the company's products include cimzia for treating ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; briviact, vimpat, and keppra for the treatment of epilepsy partial-onset seizures; nayzilam, a nasal spray; and neupro for treating parkinson's disease and restless legs syndrome. it also offers evenity, an injection for osteoporosis; and bimzelx to treat moderate to severe plaque psoriasis. the company's products in pipeline include staccato to treat stereotypical prolonged seizures; bepranemab for the treatment of alzheimer's disease; ucb0599 for parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. financière de tubize sa is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €5.85.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 12.98. meaning, the purchaser of the share is investing €12.98 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.88%.volatility
tubize-fin's last week, last month's, and last quarter's current intraday variation average was a positive 0.23%, a negative 0.11%, and a positive 1.09%.
tubize-fin's highest amplitude of average volatility was 1.03% (last week), 1.08% (last month), and 1.09% (last quarter).
yearly top and bottom value
tubize-fin's stock is valued at €76.00 at 22:30 est, way under its 52-week high of €100.80 and way higher than its 52-week low of €65.40.
more news about tubize-fin.
4. biomerieux (bim.pa)
0.88% forward dividend yield and 12.93% return on equity
biomérieux s.a. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the americas, europe, the middle east, africa, and the asia pacific. the company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. it serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. the company was formerly known as b-d mérieux. biomérieux s.a. was founded in 1963 and is headquartered in marcy l'etoile, france. biomérieux s.a. is a subsidiary of institut mérieux sa.
earnings per share
as for profitability, biomerieux has a trailing twelve months eps of €3.82.
pe ratio
biomerieux has a trailing twelve months price to earnings ratio of 25.28. meaning, the purchaser of the share is investing €25.28 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.93%.dividend yield
as stated by morningstar, inc., the next dividend payment is on jun 6, 2022, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.88%.
yearly top and bottom value
biomerieux's stock is valued at €96.56 at 22:30 est, way under its 52-week high of €109.20 and way higher than its 52-week low of €77.48.
more news about biomerieux.